Home > Insider Trading > Filing (0001354488-16-005954)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1378624	Cellular Biomedicine Group Inc.	CBMG	Biological Products, (No Disgnostic Substances) (2836)	861032927

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1569877	K Andrew Chan	19925 Stevens Creek Blvd., Suite 100 Cupertino CA 95014		No	No	No	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-01-19	1,516	$5.61	147,273	No	4	M	Direct
Common Stock	Disposition	2016-01-19	1,516	$12.07	145,757	No	4	S	Direct
Common Stock	Acquisiton	2016-01-21	1,296	$3.00	147,053	No	4	M	Direct
Common Stock	Disposition	2016-01-21	1,296	$13.87	145,747	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non- Qualified Stock Option (right to buy) (2013 Plan)	Disposition	2016-01-19	1,516	$0.00	1,516	$5.61
Common Stock	Non- Qualified Stock Option (right to buy) (2011 Plan)	Disposition	2016-01-21	1,296	$0.00	1,296	$3.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
39,420		2023-05-16	No	4	M	Direct
40,187		2023-02-20	No	4	M	Direct

Footnotes

The transaction reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2015. Accordingly, the reporting person had no discretion with regard to the timing of the transaction.
On December 22, 2015, due to miscommunications with regard to the nature of transactions undertaken by the reporting person in September 2015, the reporting person mistakenly reported the number of shares of common stock and derivative securities of the issuer owned by him after certain transactions undertaken in December 2015. As a result, the number of outstanding securities owned by the reporting person after each transaction as reported on this form reflects corrections of the reporting errors made in December 2015.
The option vested according to the following schedule: 1/31st per month following the vesting commencement date of May 16, 2014.
The option vested according to the following schedule: 1/36th per month following the vesting commencement date of February 20, 2013.